Good Health Policy Requires High-Quality Evidence. Let’s Remember That With Drug Pricing.
In the health spending debate, what policy makers need most is an honest, realistic, and evidence-based discussion. Unfortunately, many studies in the public arena fall far short.
Impact of Formulary Restrictions on Medication Intensification in Diabetes Treatment
Formulary restrictions on brand name noninsulin antihyperglycemic drugs have little impact on treatment intensification patterns among low-income patients with diabetes in Medicare Part D.
Insurance Switching and Mismatch Between the Costs and Benefits of New Technologies
Transformative therapies with high up-front costs will exacerbate the need to address gaps between payers when costs and benefits occur at different times.
